Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides
Clinical Immunology, ISSN: 1521-6616, Vol: 107, Issue: 2, Page: 80-89
2003
- 77Citations
- 33Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations77
- Citation Indexes77
- 77
- CrossRef64
- Captures33
- Readers33
- 33
Article Description
A phase I clinical trial was conducted in patients with stage III/IV breast cancer who were treated with the anti-idiotype mAb 1E10 specific to an Ab1 mAb able to react specifically with N -glycolyl-containing gangliosides and with antigens expressed on human melanoma and breast carcinoma cells. Patients were treated with 1 or 2 mg of aluminum hydroxide-precipitated 1E10 mAb every other week for six injections. Two patients at each dose were reimmunized 7–9 months after completing the induction phase. In hyperimmune sera from eight of the nine patients who received at least four doses of anti-Id vaccine preparations, strong specific responses were observed both against 1E10 mAb and NeuGc-GM 3 ganglioside (Ab3 Id + Ag + ). Nonclassical Ab1′ antibodies (Id − Ag + ) were also elicited by 1E10 mAb vaccine treatment. There were no differences between the two levels of dose tested in relation to toxicity and immunogenicity. No evidence of serious or unexpected effects was observed.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1521661603000366; http://dx.doi.org/10.1016/s1521-6616(03)00036-6; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0038577172&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/12763476; https://linkinghub.elsevier.com/retrieve/pii/S1521661603000366; http://linkinghub.elsevier.com/retrieve/pii/S1521661603000366; http://api.elsevier.com/content/article/PII:S1521661603000366?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1521661603000366?httpAccept=text/plain; http://dx.doi.org/10.1016/s1521-6616%2803%2900036-6; https://dx.doi.org/10.1016/s1521-6616%2803%2900036-6
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know